SI-BONE, Inc. (SIBN) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

532.71 k

Shareholding (Mar 2025)

FII

9.52%

Held by 86 FIIs

DII

43.92%

Held by 43 DIIs

Promoter

8.14%

How big is SI-BONE, Inc.?

22-Jun-2025

As of Jun 18, SI-BONE, Inc. has a market capitalization of 730.84 million, with net sales of 176.60 million and a net profit of -26.56 million over the last four quarters. Shareholder's funds are 166.96 million, and total assets are 230.44 million.

What does SI-BONE, Inc. do?

22-Jun-2025

SI-BONE, Inc. develops minimally invasive surgical devices for sacroiliac joint disorders, with a market cap of approximately $730.84 million and quarterly net sales of $47 million, but currently reports a net loss of $7 million.

Should I buy, sell or hold SI-BONE, Inc.?

22-Jun-2025

Who are in the management team of SI-BONE, Inc.?

22-Jun-2025

As of March 2022, the management team of SI-BONE, Inc. includes Mr. Jeffrey Dunn as Chairman, President, and CEO, with Mr. Timothy Davis as Lead Independent Director and independent directors Mr. Mark Foley, Dr. John Freund, Ms. Jeryl Hilleman, and Mr. Gregory Hinckley.

Is SI-BONE, Inc. technically bullish or bearish?

07-Oct-2025

As of October 3, 2025, the trend for SI-BONE, Inc. has shifted to mildly bearish, indicated by a bearish MACD and RSI, despite some bullishness in the monthly KST.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Poor long term growth as Operating profit has grown by an annual rate 4.85% of over the last 5 years

The company has declared Positive results for the last 9 consecutive quarters

Risky - Negative EBITDA

High Institutional Holdings at 100%

Market Beating Performance

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 696 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.64

Return on Equity

-13.95%

Price to Book

4.09

Revenue and Profits:

Net Sales:

49 Million

(Quarterly Results - Jun 2025)

Net Profit:

-6 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

18.62%

6 Months

1.8%

1 Year

47.77%

2 Years

2.23%

3 Years

52.94%

4 Years

1.8%

5 Years

-17.39%

SI-BONE, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

Is SI-BONE, Inc. technically bullish or bearish?

As of 3 October 2025, the technical trend has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by a bearish MACD on the weekly timeframe and a bearish RSI on the monthly timeframe. The daily moving averages also indicate a bearish trend. While the monthly KST shows bullishness, the overall indicators suggest weakness. There is no available return data to compare SI-BONE, Inc. against the S&P 500....

Is SI-BONE, Inc. technically bullish or bearish?

As of 3 October 2025, the technical trend for SI-BONE, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, with key indicators supporting this view. The MACD shows a bearish signal on the weekly chart, while the monthly chart is mildly bullish. The RSI indicates a bearish condition on the monthly timeframe, and the daily moving averages are bearish. Additionally, Bollinger Bands are mildly bearish on the weekly and sideways on the monthly. In terms of performance, SI-BONE has underperformed the S&P 500 across multiple periods, with a 1-month return of -10.60% compared to the S&P 500's 4.15%, and a 5-year return of -36.85% versus the S&P 500's 100.56%....

Is SI-BONE, Inc. technically bullish or bearish?

As of 3 October 2025, the technical trend for SI-BONE, Inc. has changed from bearish to mildly bearish. The weekly MACD is bearish, while the monthly MACD shows a mildly bullish stance. The weekly RSI indicates no signal, and the monthly RSI is bearish. Moving averages on a daily basis are bearish, and the KST shows a bearish trend weekly but bullish monthly. Bollinger Bands are mildly bearish weekly and sideways monthly. Dow Theory indicates no trend for both weekly and monthly periods. In terms of performance, SI-BONE has outperformed the S&P 500 over the past week with a return of 3.20% compared to 1.09%, but it has underperformed over the past month, year-to-date, one year, three years, and five years. Overall, the current technical stance is mildly bearish, reflecting mixed signals across different time frames....

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

22.61%

EBIT Growth (5y)

4.85%

EBIT to Interest (avg)

-13.19

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.64

Sales to Capital Employed (avg)

0.76

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

4.82

EV to EBIT

-22.73

EV to EBITDA

-26.71

EV to Capital Employed

11.74

EV to Sales

3.95

PEG Ratio

Dividend Yield

ROCE (Latest)

-51.64%

ROE (Latest)

-15.87%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bullish

RSI

No Signal

Bearish

Bollinger Bands

Bullish

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bullish

Bullish

Dow Theory

No Trend

OBV

No Trend

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 61 Schemes (38.42%)

Foreign Institutions

Held by 86 Foreign Institutions (9.52%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 21.50% vs 20.12% in Jun 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 30.34% vs 20.54% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "48.60",
          "val2": "40.00",
          "chgp": "21.50%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-5.60",
          "val2": "-9.10",
          "chgp": "38.46%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.70",
          "val2": "0.90",
          "chgp": "-22.22%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-6.20",
          "val2": "-8.90",
          "chgp": "30.34%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-144.00%",
          "val2": "-252.10%",
          "chgp": "10.81%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 20.37% vs 30.55% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 28.64% vs 29.36% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "167.20",
          "val2": "138.90",
          "chgp": "20.37%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-30.90",
          "val2": "-41.50",
          "chgp": "25.54%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "3.40",
          "val2": "3.50",
          "chgp": "-2.86%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-30.90",
          "val2": "-43.30",
          "chgp": "28.64%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-210.80%",
          "val2": "-337.90%",
          "chgp": "12.71%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Jun'25

Jun'24

Change(%)

Net Sales

48.60

40.00

21.50%

Operating Profit (PBDIT) excl Other Income

-5.60

-9.10

38.46%

Interest

0.70

0.90

-22.22%

Exceptional Items

0.00

Consolidate Net Profit

-6.20

-8.90

30.34%

Operating Profit Margin (Excl OI)

-144.00%

-252.10%

10.81%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Jun 2025 is 21.50% vs 20.12% in Jun 2024

Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 30.34% vs 20.54% in Jun 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

167.20

138.90

20.37%

Operating Profit (PBDIT) excl Other Income

-30.90

-41.50

25.54%

Interest

3.40

3.50

-2.86%

Exceptional Items

0.00

Consolidate Net Profit

-30.90

-43.30

28.64%

Operating Profit Margin (Excl OI)

-210.80%

-337.90%

12.71%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 20.37% vs 30.55% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 28.64% vs 29.36% in Dec 2023

All Annual Results

Company CV

About SI-BONE, Inc.

SI-BONE, Inc.

Pharmaceuticals & Biotechnology

SI-BONE, Inc. is focused on development of medical devices. The Company is engaged in the development, manufacture and commercialization of minimally invasive surgical devices for the treatment of patients with low back symptoms related to certain sacroiliac (SI) joint disorders. The Company offers iFuse Implant System, which provides a minimally invasive surgical solution to fuse the SI joint using patented triangular titanium implants that create an interference fit within the ilium and sacrum. The triangular implant shape, combined with the press fit insertion, is designed to provide fixation by minimizing rotational motion. The implants has a porous surface that provide an environment for bone ongrowth and ingrowth, facilitating long-term fusion of the joint. The iFuse Implant System is intended for sacroiliac fusion for conditions, including sacroiliac joint dysfunction that is a direct result of sacroiliac joint disruption and degenerative sacroiliitis.

Company Coordinates

Company Details

471 El Camino Real Ste 101 , SANTA CLARA CA : 95050-4482

Tel: 1 408 2070700

https://si-bone.com/

Registrar Details

SI-BONE, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is SI-BONE, Inc.?

Watch in Real-Time

What does SI-BONE, Inc. do?

Should I buy, sell or hold SI-BONE, Inc.?

Who are in the management team of SI-BONE, Inc.?

Is SI-BONE, Inc. technically bullish or bearish?

MarketsMojo — Loved in India, Now Global

Dashboard

Poor long term growth as Operating profit has grown by an annual rate 4.85% of over the last 5 years

The company has declared Positive results for the last 9 consecutive quarters

Risky - Negative EBITDA

High Institutional Holdings at 100%

Market Beating Performance

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Is SI-BONE, Inc. technically bullish or bearish?

Is SI-BONE, Inc. technically bullish or bearish?

Is SI-BONE, Inc. technically bullish or bearish?

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Annual Results Snapshot (Consolidated) - Dec'24

About SI-BONE, Inc.

Company Coordinates